TUB Stock Overview
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Financière de Tubize SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €92.40 |
| 52 Week High | €94.00 |
| 52 Week Low | €60.80 |
| Beta | 0.47 |
| 1 Month Change | 3.01% |
| 3 Month Change | 27.62% |
| 1 Year Change | 18.46% |
| 3 Year Change | 10.13% |
| 5 Year Change | 51.97% |
| Change since IPO | 1,549.41% |
Recent News & Updates
Shareholder Returns
| TUB | BE Pharmaceuticals | BE Market | |
|---|---|---|---|
| 7D | 0.4% | -0.4% | -1.1% |
| 1Y | 18.5% | 4.8% | -6.4% |
Return vs Industry: TUB exceeded the Belgian Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: TUB exceeded the Belgian Market which returned -6.4% over the past year.
Price Volatility
| TUB volatility | |
|---|---|
| TUB Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in BE Market | 7.9% |
| 10% least volatile stocks in BE Market | 2.5% |
Stable Share Price: TUB has not had significant price volatility in the past 3 months.
Volatility Over Time: TUB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1928 | n/a | Eric Nys | www.financiere-tubize.be |
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Financière de Tubize SA Fundamentals Summary
| TUB fundamental statistics | |
|---|---|
| Market cap | €4.11b |
| Earnings (TTM) | €88.15m |
| Revenue (TTM) | n/a |
46.7x
P/E Ratio0.0x
P/S RatioIs TUB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TUB income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €2.03m |
| Gross Profit | -€2.03m |
| Other Expenses | -€90.18m |
| Earnings | €88.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | 1.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.4% |
How did TUB perform over the long term?
See historical performance and comparison